Markus Reindl

Active 1995–2025

126
Papers
25,167
Citations
80
h-index
123
i10-index

Citations

Citations per year for Markus Reindl1986: 1 citations1988: 1 citations1997: 2 citations1999: 3 citations2000: 9 citations2001: 19 citations2002: 40 citations2003: 69 citations2004: 89 citations2005: 98 citations2006: 82 citations2007: 60 citations2008: 78 citations2009: 84 citations2010: 106 citations2011: 137 citations2012: 133 citations2013: 163 citations2014: 181 citations2015: 264 citations2016: 236 citations2017: 397 citations2018: 406 citations2019: 986 citations2020: 1,264 citations2021: 944 citations2022: 871 citations2023: 620 citations2024: 1,010 citations2025: 379 citations2026: 3 citations1987: no citations, so this year is not shown1989–1996: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,660 citing papers, 20.6% of this breakdownGermany: 766 citing papers, 9.5% of this breakdownChina: 653 citing papers, 8.1% of this breakdownUnited Kingdom: 629 citing papers, 7.8% of this breakdownItaly: 470 citing papers, 5.8% of this breakdownAustria: 365 citing papers, 4.5% of this breakdownFrance: 329 citing papers, 4.1% of this breakdownSpain: 269 citing papers, 3.3% of this breakdownJapan: 249 citing papers, 3.1% of this breakdownCanada: 240 citing papers, 3% of this breakdownAustralia: 222 citing papers, 2.7% of this breakdownNetherlands: 192 citing papers, 2.4% of this breakdown
0%20.6%Other 25.1%

Fields

  • Medicine75.7%
  • Immunology and Microbiology8.1%
  • Neuroscience7.6%
  • Biochemistry, Genetics and Molecular Biology6.9%
  • Agricultural and Biological Sciences0.3%
  • Nursing0.3%
  • Other1.1%

Topics

  • Multiple Sclerosis Research Studies12.1%
  • Peripheral Neuropathies and Disorders9.5%
  • Autoimmune Neurological Disorders and Treatments9%
  • Neuroinflammation and Neurodegeneration Mechanisms4.1%
  • Parkinson's Disease Mechanisms and Treatments3.2%
  • Systemic Lupus Erythematosus Research2.7%
  • Other59.4%

Coauthors

All papers

Open in search
  1. A clinical approach to diagnosis of autoimmune encephalitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2016 cited by 4,396

  2. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 1,130

  3. Myelin-oligodendrocyte glycoprotein antibody-associated disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Krzysztof Selmaj, Aksel Sıva, Bruno Stankoff, Mar Tintoré, Anthony Traboulsee, Patrick Waters, Emmanuelle Waubant, Brian G. Weinshenker, Tobias Derfuß, Sandra Vukusic, Bernhard Hemmer - The Lancet Neurology 2021 cited by 517

  4. Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia

    Authors: , , , , , , , - Glia 2012 cited by 708

  5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brigitte Wildemann - Journal of Neuroinflammation 2016 cited by 891

  6. Myelin oligodendrocyte glycoprotein antibodies in neurological disease

    Authors: , - Nature Reviews Neurology 2018 cited by 618

  7. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2022 cited by 81

  8. International multicenter examination of MOG antibody assays

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2020 cited by 278

  9. Blood–Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models

    Authors: , - International Journal of Molecular Sciences 2023 cited by 74

  10. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Woodhall, Jacqueline Palace, Friedemann Paul, Hans-Peter Hartung, Orhan Aktaş, Sven Jarius, Brigitte Wildemann, Christian A. Vedeler, Anne Ruiz, Maria Isabel Leite, Peter Trillenberg, Monika Probst, Sandra Saschenbrecker, Angela Vincent, Romain Marignier - Journal of Neurology Neurosurgery & Psychiatry 2016 cited by 296

  11. Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Neurology 2014 cited by 510

  12. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Neuroinflammation 2020 cited by 168

  13. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Neuroinflammation 2016 cited by 428

  14. Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons

    Authors: , , , , , - American Journal Of Pathology 2011 cited by 267

  15. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

    Authors: , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2015 cited by 386

  16. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvia Vieker, Carolin Zeches, Thomas Berger, Markus Reindl, Kevin Rostásy - Neurology 2017 cited by 341

  17. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rinze F. Neuteboom, Cheryl Hemingway, Rob Forsyth, Marcelo Matiello, Stewart Webb, David Hunt, Katy Murray, Yael Hacohen, Ming Lim, Maria Isabel Leite, Jacqueline Palace, Tom Solomon, Andreas Lutterotti, Kazuo Fujihara, Ichiro Nakashima, Jeffrey L. Bennett, Lekha Pandit, Tanuja Chitnis, Brian G. Weinshenker, Brigitte Wildemann, Douglas Kazutoshi Sato, Su‐Hyun Kim, Saif Huda, Ho Jin Kim, Markus Reindl, Michael Levy, Sven Jarius, Sílvia Tenembaum, Friedemann Paul, Sean J. Pittock, Romain Marignier, Anu Jacob - Multiple Sclerosis and Related Disorders 2020 cited by 179

  18. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Authors: , , , , , , , , , , , , , , , , , - Journal of Neuroinflammation 2021 cited by 86

  19. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Gajofatto - Journal of Neurology 2017 cited by 166

  20. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo

    Authors: , , , , , , , , , , , - Annals of Neurology 2009 cited by 561

  21. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Neuroinflammation 2011 cited by 444

  22. Cell-based assays for the detection of MOG antibodies: a comparative study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Neurology 2020 cited by 77

  23. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

    Authors: , , , , , , , , , - Brain 2008 cited by 439

  24. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases

    Authors: , , , , , , , , , , , , , - Neurology 2019 cited by 111